NAD+ typical research dosing
Across the available literature, NAD+ is most commonly administered at 50000–250000 mcg per dose, 1 time(s) per day, via subcutaneous injection. Subcutaneous research protocols commonly use 50–250 mg daily. Higher IV doses (250–750 mg) are studied in clinic settings under supervision.
NAD+ unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 500 mg NAD+ vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 50000 mcg | 150000 mcg | 250000 mcg |
|---|---|---|---|---|
| 1 mL | 500000 mcg/mL | 10.0 units | 30.0 units | 50.0 units |
| 2 mL | 250000 mcg/mL | 20.0 units | 60.0 units | 100.0 units |
| 3 mL | 166667 mcg/mL | 30.0 units | 90.0 units | 150.0 units |
| 5 mL | 100000 mcg/mL | 50.0 units | 150.0 units | 250.0 units |
NAD+ cycle length
Most reported NAD+ protocols run 4 weeks on, then 2 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
NAD+ half-life and timing
NAD+ has a half-life of approximately 2 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.